Conivaptan Yamanouchi.
Yamanouchi is developing conivaptan, a diuretic and active vasopressin V1a and V2 antagonist, which has an aquaretic effect, for the potential treatment of hyponatremia and heart failure. In January 2004, Yamanouchi submitted an NDA in the US for injectable conivaptan for the treatment of hyponatremia and, in December 2004, the FDA issued approval, although additional safety data were requested.
Doggrell
Sheila A
SA
Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s.doggrell@xtra.co.nz
D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D004232:Diuretics / Q000494:pharmacology / Q000627:therapeutic use*; D004487:Edema / Q000188:drug therapy; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy*; D015394:Molecular Structure; D013329:Structure-Activity Relationship; D014667:Vasopressins / Q000037:antagonists & inhibitors*
D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D004232:Diuretics; C106389:conivaptan; D014667:Vasopressins